Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCELERON PHARMA INCXLRN · Entity 15780 | Director | January 25, 2019 | January 29, 2019 |
| Alkermes plc.ALKS · Entity 2392 | Director · Director and CEO, Alkermes plc | March 02, 2026 | March 05, 2026 |
| Epizyme, Inc.EPZM · Entity 12703 | Director | May 29, 2020 | June 02, 2020 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCELERON PHARMA INC
Report date January 25, 2019 · Filed January 29, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,500 |
Reported balance
After 2019-01-25 transaction · row 1
1 source rowRow 1 · 2019-01-25 · Grant · Acquired 1,250 · Balance 32,500 |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64 · Expires 2029-01-25 | Direct | 7,500 |
Reported balance
After 2019-01-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-25 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.
Alkermes plc.
Report date March 02, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 88,843 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 88,843 · Balance 88,843 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: Shares subject to the restricted stock unit award vest in full on 12/31/2026 in connection with the Company's previously announced leadership transition. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: Shares subject to the restricted stock unit award vest in full on 12/31/2026 in connection with the Company's previously announced leadership transition.
Epizyme, Inc.
Report date May 29, 2020 · Filed June 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.55 · Expires 2030-05-28 | Direct | 14,013 |
Reported balance
After 2020-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-29 · Grant · Acquired 14,013 · Balance 14,013 F1: This option will vest in full on May 29, 2021, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in full on May 29, 2021, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full.
NEUROCRINE BIOSCIENCES INC
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,567 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 2,567 · Balance 2,567 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: The RSUs will vest in full on May 27, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2023 Filed Feb 22, 2023 22:00 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 53,145 | $28.07 | $1,491,780.15 |
DisclosureSEC source: 0001127602-23-006518 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,867 Read SEC document |
| February 20, 2023 Filed Feb 22, 2023 22:00 UTC | Alkermes plc. ALKS · Entity 2392 | GrantOrdinary Shares | 119,713 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006518 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088,012 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 20, 2020 with a three-year performance period that ended on December 31, 2022 (the "2020 PRSUs"). The vesting of this portion of the 2020 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2020 PRSUs. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $12.71 Strike: $12.71 | $190,650.00 |
DisclosureSEC source: 0001209191-23-002053 · doc4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted May 23, 2013 and vested monthly over one year. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,000 | $119.20 | $1,788,045.00 |
DisclosureSEC source: 0001209191-23-002053 · doc4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,512 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $117.79 to $120.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $12.71 | $190,650.00 |
DisclosureSEC source: 0001209191-23-002053 · doc4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 9,724 | $0.00 Strike: $84.95 | $0.00 |
DisclosureSEC source: 0001209191-22-030984 · doc4.xml · derivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,724 Underlying: Common Stock · 9,724 shares Expires 2032-05-18 F1 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 18, 2022. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 7,500 | $6.66 Strike: $6.66 | $49,950.00 |
DisclosureSEC source: 0001209191-22-028369 · doc4.xml · derivative · entry 6 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted May 23, 2012 and vested monthly over one year. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 7,500 | $6.66 Strike: $6.66 | $49,950.00 |
DisclosureSEC source: 0001209191-22-028369 · doc4.xml · derivative · entry 5 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted May 23, 2012 and vested monthly over one year. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 7,500 | $76.30 | $572,251.50 |
DisclosureSEC source: 0001209191-22-028369 · doc4.xml · nonDerivative · entry 4 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,512 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $75.57 to $78.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 7,500 | $6.66 | $49,950.00 |
DisclosureSEC source: 0001209191-22-028369 · doc4.xml · nonDerivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 7,500 | $76.29 | $572,211.00 |
DisclosureSEC source: 0001209191-22-028369 · doc4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,512 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $75.54 to $78.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 7,500 | $6.66 | $49,950.00 |
DisclosureSEC source: 0001209191-22-028369 · doc4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2022 Filed May 6, 2022 21:04 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 120,847 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0001127602-22-013707 · form4.xml · derivative · entry 7 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 120,847 shares Expires 2022-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| May 06, 2022 Filed May 6, 2022 21:04 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 93,747 | $27.85 | $2,611,313.31 |
DisclosureSEC source: 0001127602-22-013707 · form4.xml · nonDerivative · entry 5 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,299 F1 · kind: This sale was made to cover the option exercise price and related fees. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.32. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| May 06, 2022 Filed May 6, 2022 21:04 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 120,847 | $16.55 | $2,000,017.85 |
DisclosureSEC source: 0001127602-22-013707 · form4.xml · nonDerivative · entry 4 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:04 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 329,153 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0001127602-22-013707 · form4.xml · derivative · entry 6 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,847 Underlying: Ordinary Shares · 329,153 shares Expires 2022-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:04 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 32,288 | $28.59 | $923,226.93 |
DisclosureSEC source: 0001127602-22-013707 · form4.xml · nonDerivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 941,199 F1 · kind: This sale was made to cover the option exercise price and related fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.44 to $28.82. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:04 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 221,222 | $27.95 | $6,183,243.39 |
DisclosureSEC source: 0001127602-22-013707 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,487 F1 · kind: This sale was made to cover the option exercise price and related fees. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.44 to $28.43. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:04 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 329,153 | $16.55 | $5,447,482.15 |
DisclosureSEC source: 0001127602-22-013707 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,194,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:37 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 32,400 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-22-006324 · form4.xml · derivative · entry 4 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,400 Underlying: Ordinary Shares · 32,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/21/2020. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/21/2020. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:37 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 14,386 | $25.08 | $360,800.88 |
DisclosureSEC source: 0001127602-22-006324 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865,556 Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:37 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 32,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-006324 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 879,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:37 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 299,044 | $0.00 Strike: $25.08 | $0.00 |
DisclosureSEC source: 0001127602-22-006324 · form4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,044 Underlying: Ordinary Shares · 299,044 shares Expires 2032-02-18 F2 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:21 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 18,125 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-22-005452 · form4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 18,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:21 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 8,038 | $26.79 | $215,338.02 |
DisclosureSEC source: 0001127602-22-005452 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,542 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:21 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 18,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005452 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 20:32 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 36,267 | $30.60 | $1,109,770.20 |
DisclosureSEC source: 0001127602-21-025409 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 837,455 Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 20:32 UTC | Alkermes plc. ALKS · Entity 2392 | GrantOrdinary Shares | 81,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-025409 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 873,722 F1 · price: These ordinary shares were acquired by the reporting person as a result of the partial vesting of performance-vesting restricted stock unit awards ("PRSUs") granted to the reporting person on February 20, 2020. The vesting of this portion of the PRSUs was triggered by the achievement of certain pre-specified pipeline performance goals. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 8,833 | $0.00 Strike: $92.35 | $0.00 |
DisclosureSEC source: 0001209191-21-034386 · doc4.xml · derivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833 Underlying: Common Stock · 8,833 shares Expires 2031-05-19 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:27 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001127602-21-017397 · form4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 150,000 shares Expires 2021-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:27 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 150,000 | $21.90 | $3,285,405.00 |
DisclosureSEC source: 0001127602-21-017397 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,040 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.76 to $22.05. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| May 18, 2021 Filed May 19, 2021 20:27 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 150,000 | $18.11 | $2,715,750.00 |
DisclosureSEC source: 0001127602-21-017397 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 942,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:24 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001127602-21-016394 · form4.xml · derivative · entry 4 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 150,000 shares Expires 2021-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:24 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 60,297 | $22.30 | $1,344,797.96 |
DisclosureSEC source: 0001127602-21-016394 · form4.xml · nonDerivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,040 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.25 to $22.38. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:24 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 89,703 | $21.95 | $1,968,541.31 |
DisclosureSEC source: 0001127602-21-016394 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,337 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.25 to $22.24. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:24 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 150,000 | $18.11 | $2,715,750.00 |
DisclosureSEC source: 0001127602-21-016394 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 942,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 06, 2021 Filed May 7, 2021 20:47 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001127602-21-015894 · form4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Ordinary Shares · 100,000 shares Expires 2021-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| May 06, 2021 Filed May 7, 2021 20:47 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 100,000 | $21.79 | $2,179,410.00 |
DisclosureSEC source: 0001127602-21-015894 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,040 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.54 to $22.16. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| May 06, 2021 Filed May 7, 2021 20:47 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 100,000 | $18.11 | $1,810,500.00 |
DisclosureSEC source: 0001127602-21-015894 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:59 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 342,187 | $0.00 Strike: $19.73 | $0.00 |
DisclosureSEC source: 0001127602-21-007797 · form4.xml · derivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,187 Underlying: Ordinary Shares · 342,187 shares Expires 2031-02-22 F1 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022. Read SEC document |
| February 21, 2021 Filed Feb 24, 2021 02:37 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 32,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-007462 · form4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,800 Underlying: Ordinary Shares · 32,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/21/2020. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/21/2020. Read SEC document |
| February 21, 2021 Filed Feb 24, 2021 02:37 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 14,386 | $19.58 | $281,677.88 |
DisclosureSEC source: 0001127602-21-007462 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,040 Read SEC document |
| February 21, 2021 Filed Feb 24, 2021 02:37 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 32,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-007462 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 806,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 00:28 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006566 · form4.xml · derivative · entry 6 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/17/2018. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/17/2018. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 00:28 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,869 | $19.97 | $77,263.93 |
DisclosureSEC source: 0001127602-21-006566 · form4.xml · nonDerivative · entry 4 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 774,026 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 00:28 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006566 · form4.xml · nonDerivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:28 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 18,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006566 · form4.xml · derivative · entry 5 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,125 Underlying: Ordinary Shares · 18,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/16/2019. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/16/2019. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:28 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 8,074 | $19.79 | $159,784.46 |
DisclosureSEC source: 0001127602-21-006566 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 769,145 Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:28 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 18,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006566 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:15 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 14,013 | $0.00 Strike: $17.55 | $0.00 |
DisclosureSEC source: 0000899243-20-014897 · doc4.xml · derivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,013 Underlying: Common Stock · 14,013 shares Expires 2030-05-28 F1 · derivative.exercise_date: This option will vest in full on May 29, 2021, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.